InterGenetics Uses Genomics

Click here to view chart with audio.
Flash 6 player or higher required. Click Here to download Flash Player.

Because all cancer has some genetic basis for development, researching the genetic basis of this disease allows us to find gene combinations that are predictive of developing cancer, such that many of these genes or gene products can also become drug leads or targeted therapy for treating specific types of cancer.

InterGenetics® scientists have discovered a complex algorithm of multiple gene combinations related to breast cancer and other cancers by testing more than a million combinations of genes. This breakthrough discovery is an accurate method of predicting the risk of developing breast cancer and other cancers and has application in other disease processes and preventative medicines.

The OncoVue® Breast Cancer Risk score is calculated at three life states - pre-menopause, peri-menopause, and post-menopause - by analyzing a patient's individual results as compared to all other women tested using proprietary algorithms to determine their unique level of risk. The genetic analysis process of this information is extremely accurate (>99.999%). OncoVue® scores are an assessment based upon the current knowledge of genes contributing to a unique risk level.

This test involves Polymerase Chain Reaction (PCR). This service is performed pursuant to an agreement with Roche Molecular System, Inc.